Our Clinical Sites and Trials

A5407 - Ensayo ambulatorio de fase 3 controlado con placebo del agente Shionogi para el tratamiento de la infección sintomática por SARS-CoV-2

Closed to accrual

See locations

A5409: A Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (RAD-TB)

The standard of care (SOC) treatment of tuberculosis (TB) was developed over 40 years ago, and the treatment is long…

Active, Not Recruiting

Participants will be in this study for about 52 weeks. This includes a total of 26 weeks of TB treatment. If assigned to the experimental arm, participants will have 8 weeks of experimental treatment, followed by 18 weeks of SOC treatment. If assigned to the SOC arm, participants will have 26 weeks of SOC treatment.

See locations

A5415: A Limited-Center, Prospective, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living with HIV

People with HIV can have an increase in inflammation in their body organs even after taking anti-HIV medicines (ART, or…

Closed to accrual

24 weeks

See locations

A5417: Randomized, Double-Blind, Placebo-Controlled Study of the Combination of two Long-Acting Broadly Neutralizing Antibodies at ART Initiation in Adults Living with HIV-1 in sub-Saharan Africa

This study enrolls people living with HIV in sub-Saharan Africa at the time that they are about to start antiretroviral…

Open and enrolling

Up to 180 weeks.

See locations

A5418: A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Mpox Disease

A5418 (STOMP) is a study of tecovirimat (also known as TPOXX) for the treatment of human monkeypox virus (HMPXV) disease.

Closed to accrual

See locations

A5422: CH505 TF chTrimer Vaccination in Adults Living with HIV-1 on Suppressive ART

This study is looking to see if an investigational anti-HIV vaccine (stabilized CH505 TF chTrimer) is safe and well-tolerated in…

Active, Not Recruiting

Participants will be on study for about 2 years (100 weeks).

See locations